ADIPOQ and metabolic syndrome: In participants with T2DM who developed MetS during this study, a downward trend in serum adiponectin concentration was observed over the 24-month follow-up period, but without a significant difference in adiponectin concentrations between individual observation periods (Figure 2, Table 2 and Table S1).